Literature DB >> 6814928

Plasma concentrations and haemodynamic effects of nitroglycerin during and after intravenous infusion in healthy volunteers.

P R Imhof, A Sieber, J Hodler, P Müller, B Ott, P Fankhauser, L C Chu, A Gérardin.   

Abstract

The effects of nitroglycerin, infused intravenously at 3.4 and 7.5 micrograms/min over 30 min, on haemodynamic parameters were determined in the morning and the afternoon in a randomized, placebo-controlled study in 5 healthy volunteers. The mean steady-state concentrations of nitroglycerin reached in the plasma during the infusions of 3.4 and 7.5 micrograms/min were 0.35 +/- 0.06 ng/ml and 0.64 +/- 0.22 ng/ml, respectively. Wide inter-individual variation was noted. The nitroglycerin-induced increase in the orthostatic rise in heart rate and the change in digital-pulse-wave morphology roughly paralleled the plasma concentration, whereas the reduction in systolic blood pressure in the upright position was still evident 15 mins after the infusion, i.e. when nitroglycerin was no longer measurable in plasma. No significant diurnal variation in vascular sensitivity to the vasodilative action of nitroglycerin was demonstrable. The change in pulse-wave morphology resulting from the reduction in peripheral resistance (shift of the dicrotic wave in the descending limb towards the base-line) proved to be the most sensitive haemodynamic parameter.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6814928     DOI: 10.1007/bf00545962

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Adsorption of NTG.

Authors:  J P Branje; B Berghuis
Journal:  Am Heart J       Date:  1980-09       Impact factor: 4.749

2.  Difference in nitroglycerin dose-response in the venous and arterial beds.

Authors:  P R Imhof; B Ott; P Frankhauser; L C Chu; J Hodler
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

3.  Pharmacokinetic-hemodynamic studies of intravenous nitroglycerin in congestive cardiac failure.

Authors:  P W Armstrong; J A Armstrong; G S Marks
Journal:  Circulation       Date:  1980-07       Impact factor: 29.690

4.  Determinants of drug response in severe chronic heart failure. 1. Activation of vasoconstrictor forces during vasodilator therapy.

Authors:  M Packer; J Meller; N Medina; M Yushak; R Gorlin
Journal:  Circulation       Date:  1981-09       Impact factor: 29.690

5.  Quantitative determination of trinitroglycerin in human plasma.

Authors:  J Y Wei; P R Reid
Journal:  Circulation       Date:  1979-03       Impact factor: 29.690

6.  Effects of intravenous nitroglycerin on left ventricular function and ST segment changes in acute myocardial infarction.

Authors:  J T Flaherty; P C Come; M G Baird; J Rouleau; D R Taylor; M L Weisteldt; H L Greene; L C Becker; B Pitt
Journal:  Br Heart J       Date:  1976-06

7.  Nitroglycerin compatibility with intravenous fluid filters, containers, and administration sets.

Authors:  D M Baaske; A H Amann; D M Wagenknecht; M Mooers; J E Carter; H J Hoyt; R G Stoll
Journal:  Am J Hosp Pharm       Date:  1980-02

8.  Human pharmacological studies of a new transdermal system containing nitroglycerin.

Authors:  P Müller; P R Imhof; F Burkart; L C Chu; A Gérardin
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Improved GLC determination of plasma nitroglycerin concentrations.

Authors:  P S Yap; E F McNiff; H L Fung
Journal:  J Pharm Sci       Date:  1978-04       Impact factor: 3.534

10.  Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects.

Authors:  E F McNiff; A Yacobi; F M Young-Chang; L H Golden; A Goldfarb; H L Fung
Journal:  J Pharm Sci       Date:  1981-09       Impact factor: 3.534

View more
  17 in total

1.  In vitro and in vivo-release of nitroglycerin from a new transdermal therapeutic system.

Authors:  M Wolff; G Cordes; V Luckow
Journal:  Pharm Res       Date:  1985-01       Impact factor: 4.200

Review 2.  Pharmacokinetics of various preparations of organic nitrates.

Authors:  J P Kampmann
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 3.  Intravenous glyceryl trinitrate (nitroglycerin). A review of its pharmacological properties and therapeutic efficacy.

Authors:  E M Sorkin; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of organic nitrates.

Authors:  M G Bogaert
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

5.  Lack of tolerance of headache and radial artery diameter during a 7 hour intravenous infusion of nitroglycerin.

Authors:  H K Iversen; T H Nielsen; P Tfelt-Hansen; J Olesen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Mechanisms mediating nitroglycerin-induced delayed-onset hyperalgesia in the rat.

Authors:  L F Ferrari; J D Levine; P G Green
Journal:  Neuroscience       Date:  2016-01-11       Impact factor: 3.590

Review 7.  Relationship of pharmacokinetic and pharmacodynamic properties of the organic nitrates.

Authors:  U Thadani; T Whitsett
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

8.  The haemodynamic effects and pharmacokinetics of intravenous nicorandil in healthy volunteers.

Authors:  D L Wolf; J J Ferry; A E Hearron; M O Froeschke; J R Luderer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Human pharmacological studies of a new transdermal system containing nitroglycerin.

Authors:  P Müller; P R Imhof; F Burkart; L C Chu; A Gérardin
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Dose proportionality of transdermal nitroglycerin.

Authors:  R C Jewell; C R Banfield; D A Ruggirello; Y W Huang; P K Noonan; M A Gonzalez
Journal:  Pharm Res       Date:  1992-10       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.